Short communication: Antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi

Tropical Medicine and International Health

Volumn 12, Issue 7, 2007, Pages 852-855

  Tostmann, A ^a   Boeree, M J ^a   Harries, A D ^b   Sauvageot, D ^c   Banda, H T ^d   Zijlstra, E E ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MINISTRY OF HEALTH   (Malawi)

^c INSERM   (France)

^d UNIVERSITY OF MALAWI   (Malawi)

Author keywords

Adverse effects; Drug induced liver disease; HIV; Mycobacterium tuberculosis; Tuberculosis treatment

Indexed keywords

COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTICS; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; TOXICITY; TUBERCULOSIS;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAWI; MALE; PROPHYLAXIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALAWI; MALE; MIDDLE AGED; SEX DISTRIBUTION; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, PULMONARY;

AFRICA; EAST AFRICA; MALAWI; SUB-SAHARAN AFRICA;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34347221906     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01871.x     Document Type: Article

References (14)

1. Boeree MJ, Sauvageot D, Banda HT, Harries AD Zijlstra EE (2005) Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Tropical Medicine and International Health 10, 723 733.
2. Dean GL, Edwards SG, Ives NJ et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16, 75 83.
3. Dossing M, Wilcke JT, Askgaard DS Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tubercle and Lung Disease 77, 335 340.
4. Fernandez-Villar A, Sopena B, Fernandez-Villar J et al. (2004) The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. The International Journal of Tuberculosis and Lung Disease 8, 1499 1505.
5. Johnson JL, Okwera A, Nsubuga P et al. (2000) Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. The International Journal of Tuberculosis and Lung Disease 4, 1032 1040.
6. Kovacs JA, Hiemenz JW, Macher AM et al. (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Annals of Internal Medicine 100, 663 671.
7. Kwara A, Flanigan TP Carter EJ (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. The International Journal of Tuberculosis and Lung Disease 9, 248 257.
8. Peloquin CA, Nitta AT, Burman WJ et al. (1996) Low antituberculosis drug concentrations in patients with AIDS. The Annals of Pharmacotherapy 30, 919 925.
9. Perriens JH, St Louis ME, Mukadi YB et al. (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. The New England Journal of Medicine 332, 779 784.
10. Schaberg T, Rebhan K Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. The European Respiratory Journal 9, 2026 2030.
11. Whalen CC, Johnson JL, Okwera A et al. (1997) A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. The New England Journal of Medicine 337, 801 808.
12. WHO (1992) International Monitoring or Adverse Reactions to Drugs: Adverse Reaction Terminology. WHO Collaborating Center for International Drug Monitoring, Uppsala Sweden.
13. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. The New England Journal of Medicine 352, 2211 2221.
14. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine 167, 1472 1477.